title: Radiotherapy for prevention and therapy of gynecomastia due to antiandrogen treatment in prostate cancer patients: a patterns-of-care study.
abstract: BACKGROUND
  Gynecomastia is a frequent side effect of antiandrogen therapy for prostate cancer and may compromise quality of life. Although it has been successfully treated with radiotherapy (RT) for decades, the priority of RT as a preferred treatment option has recently been disputed as tamoxifen was also demonstrated to be effective. The aim of the present paper is to provide an overview of indications, frequency, and technique of RT in daily practice in Germany, Switzerland, and Austria.
  
  
  METHODS
  On behalf of the DEGRO-AG GCG-BD (German Cooperative Group on Radiotherapy of Benign Diseases) a standardized questionnaire was sent to 294 RT institutions. The questionnaires inquired about patient numbers, indications, RT technique, dose, and - if available - treatment results. Moreover, the participants were asked whether they were interested in participating in a prospective study.
  
  
  RESULTS
  From a total of 294 institutions, 146 replies were received, of which 141 offered RT for gynecomastia. Seven of those reported prophylactic RT only, whereas 129 perform both preventive and symptomatic RT. In 110 of 137 departments, a maximum of 20 patients were treated per year. Electron beams (76%) were used most often, while 24% of patients received photon beams or orthovolt x-rays. Total doses were up to 20 Gy for prophylactic and up to 40 Gy for therapeutic RT. Results were reported by 19 departments: prevention of gynecomastia was observed in 60-100% of patients. Only 13 institutions observed side effects.
  
  
  CONCLUSIONS
  Prophylactic and symptomatic RT is widely used in the German-speaking countries, but patient numbers are small. The clinical results indicate that RT is a highly effective and well-tolerated treatment.
authors: Klinik für Radioonkologie und Strahlentherapie, Klinikum Karlsruhe, Karlsruhe, Germany. burkhard.neu@klinikum-karlsruhe.de
authors: Burkhard
authors: B
authors: Neu
authors: Verena
authors: V
authors: Sautter
authors: Felix
authors: F
authors: Momm
authors: Ute
authors: U
authors: Melcher
authors: Heinrich
authors: H
authors: Seegenschmiedt
authors: Oliver
authors: O
authors: Micke
authors: Marie-Luise
authors: ML
authors: Sautter-Bihl
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D001317:Austria; D019583:Dose Fractionation, Radiation; D005500:Follow-Up Studies; D005858:Germany; D006177:Gynecomastia / Q000139:chemically induced* / Q000517:prevention & control / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011855:Radiodermatitis / Q000209:etiology; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D013557:Switzerland; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists